Skip to main content

Table 1 Baseline characteristics of the study population

From: Combined value of left ventricular ejection fraction and the Model for End-Stage Liver Disease (MELD) score for predicting mortality in patients with acute coronary syndrome who were undergoing percutaneous coronary intervention

Variable Survivors (n = 663) Non-survivors (n = 183) P-value
Age (year) 62 ± 12 67 ± 12 <  0.001
Female n (%) 158 (24) 59 (32) 0.021
History of HF n (%) 11 (2) 15 (8) < 0.001
Hypertension n (%) 301 (45) 107 (59) 0.002
Diabetes mellitus n (%) 117 (27) 77 (42) < 0.001
Hyperlipidemia n (%) 94 (14) 31 (17) 0.351
Current smoking n (%) 210 (32) 41 (22) 0.015
Previous CAD n (%) 183 (28) 66 (26) 0.026
Prior stroke/TIA n (%) 21 (3) 19 (10) < 0.001
Type of ACS n (%)
 STEMI 419 (63) 105 (57) 0.151
 NSTEMI 179 (27) 62 (34) 0.102
 UA 56 (8) 13 (7) 0.557
Major bleeding n (%) 14 (2) 9 (5) 0.039
Killip class ≥2 n (%) 33 (5) 48 (26) < 0.001
Medication at discharge
 Beta-blocker n (%) 580 (88) 136 (74) < 0.001
 Statin n (%) 539 (81) 143 (78) 0.339
 ACE-I/ARB n (%) 555 (84) 126 (99) < 0.001
Outcomes
 In-hospital death n (%) 0 (0) 30 (16) < 0.001
 Stroke n (%) 14 (2) 9 (5) 0.039
 HF admission n (%) 24 (4) 25 (14) < 0.001
 Myocardial reinfarction n (%) 62 (9) 17 (9) 0.980
 TVR n (%) 78 (12) 11 (6) 0.025
 Cardiac death n (%) 0 (0) 59 (32) < 0.001
  1. HF heart failure, CAD coronary artery disease, TIA transient ischemic attack, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ACS acute coronary syndrome, UA unstable angina, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarction, TVR target vessel revascularization